Can licorice and blueberry supplements boost reflux treatment?

NCT ID NCT07790549

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

This trial tests whether adding a gel made with alginate, licorice, and blueberry to a standard reflux medicine improves symptoms and quality of life in adults with non-erosive gastroesophageal reflux disease (NERD). About 140 participants will receive either the standard medicine alone or the medicine plus the supplement for 4 weeks. Researchers will measure changes in reflux symptoms and quality of life at 2 and 4 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A dietary supplement gel containing sodium alginate and extracts of licorice and blueberry, taken alongside esomeprazole
What this could lead to
If it works, adding this supplement to standard reflux medicine could offer a natural way to ease heartburn and improve quality of life for people with non-erosive GERD.
What could go wrong
This is a small, early-stage trial, and the supplement may not provide extra benefit beyond the standard drug. Some people may experience side effects from the supplement or the drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 140 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged ≥18 years. * Males and females. * Diagnosis of non-erosive gastroesophageal reflux disease (NERD), based on the absence of macroscopic lesions of the distal esophageal mucosa on endoscopy performed within 6 months prior to enrollment. * Heartburn and/or acid regurgitation at least 3 times per week during the 2 weeks prior to enrollment. * Written informed consent for study participation obtained prior to the start of the study. Exclusion Criteria: * Active gastric or duodenal ulcer within the previous 3 months. * Previous surgery involving the esophagus or treated upper gastrointestinal tract. * Absence of erosive esophagitis or Barrett's esophagus. * Severe renal or hepatic impairment. * Use of proton pump inhibitors (PPIs), H2-antagonists, or systemic glucocorticoids within 2 weeks prior to enrollment. * Pregnancy. * Breastfeeding. * Alcohol or drug abuse. * Hypersensitivity to any of the study product components. * Participation in another clinical trial within 30 days prior to enrollment. * Lack of acceptance of written informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-erosive gastroesophageal reflux disease (NERD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Casa di Cura Quisisana

    Rome, Lazio, 00197, Italy

  • Centro per la Gastroenterologia

    Mercato San Severino, Salerno, 84085, Italy